Moving towards effective drug delivery technologies and deal making
1st - 2nd February 2011, BSG Conference Centre, London, UK
Key Speakers:
Dr. Sven Stegemann, Director, Pfizer
Dr. Sophie Van Tomme, Pharmaceutical Scientist, Abbott
Gerrit Hauck, Head PSD R&D Operations, Sanofi -Aventis
Matthew Roe, Senior Director-Business Development and Licensing, Genzyme
Dr. Oliver Steinbach, Department Head, Philips Research Laboratories
Dr. Rajan K. Verma, Senior Manager Early Development Formulations – Generics Integrated Product Development (IPDO), Dr Reddy’s Laboratories
Dr. Deirdre McIntosh, Director, McIntosh Scientific Advice Services
Dr. Michel Deleers, CEO, OncoBel
Dr. Andrew Lewis, Operations Director, Critical Pharmaceuticals
Dr. Ben Forbes, Senior Lecturer in Pharmaceutics, King’s College, London
Ketan Pancholi, Lecturer, The Robert Gordon University
Gerry Kamstra Partner, IP & Life Sciences, Bird and Bird
Conference Introduction
Shrinking global capital markets, new healthcare policies, ageing populations, the growth of emerging economies, technological advances and the advent of regenerative and biological medicines are just some of the factors expected to shape the future drug delivery device market. (Source: Cambridge Consultants UK, September 2009)
With increased competition and the growing importance of patience compliance, pharmaceutical companies are working towards developing effective and targeted drug
delivery systems, to transform disease treatments. Now in its 6th year, Drug Delivery Systems Conference showcases the basics and latest developments for inhaled drug, RNAi based therapies and protein and peptide methods. We have put together an unparalleled scientific programme comprising insightful presentations by leading experts from Pfizer, Philips Research, Dr Reddy’s Laboratories and Genzyme. This conference will feature keynote addresses, case studies and interactive discussions
ranging from current and evolving drug delivery technologies to advancement and manufacturing of more efficient formulations.
Attendance at this conference will enable you to:
*
Benefit from thorough updates of recent developments in the drug delivery sector
*
Examine challenges in generic development of drug delivery systems
*
Learn from in-depth case study from Philips about image-guided ultrasound-mediated drug delivery
*
Identify different strategies in managing a drug delivery alliance
*
Know how to overcome the industry challenges for inhaled delivery systems
*
Discuss key regulatory and legal issues
*
Recognise the importance of new biologic delivery technologies
*
Discuss microbubble production technologies and its effect on delivery
*
Create patient centered drug delivery product
*
Network with experts and opinion leaders from pharma, biotech, device and drug delivery industries
Who should attend?
VPs, Directors, Heads, Managers of:
*
Drug Delivery
*
Preformulation /Formulation/Stability
*
Business Development
*
Licensing
*
Technology Assessment
*
Commercial Development
*
Patents
*
Lifecycle Management
*
Strategic Planning and Development
*
Financial Analyst
*
Pharmaceutical and Analytical R&D
*
Pharmaceutical Science
*
Testing
*
Product Development
*
New Product Planning]
*
New Technology Evaluation
*
Marketing
*
Brand Management
*
Product Management
*
Sales
*
Regulatory Affairs
Others:
*
Intellectual Property Attorneys
*
Venture Capitalists
*
Medical Device Companies
*
Analysts/Investment Banks
CROs:
*
Contract Sales Organisations
*
Universities and Government Research
*
Testing and Manufacturing Equipment
*
Packaging Companies
Day 1
6th Annual Drug Delivery Systems
Tuesday 1st February 2011
09:00 Registration and refreshments
09:30 Opening address from the chair
09:40 Imagine a patient would run a formulation lab: Patient centered drug delivery product development
*
From clinical perspectives to therapeutic objectives
*
Identifying patient needs beyond the clinical symptoms
*
Translating scientific excellence in real world therapy enhancement
*
Integrating patient centered drug delivery in healthcare provision
Dr Sven Stegemann
Director, Pfizer
10:20 Realising partnerships with academia, SME’s and Big E in the field of inhalation.
*
The NeoFor project (New formulation and Devices for the inhalation of Macromolecules)
*
Anticancer drug project for lung cancer (Solid lipidic micro particles formulations)
*
Formulations for 2 and 3 molecules
*
Formulations with pegylated mAb’s
*
Other projects in partnering
Dr. Michel Deleers
CEO, OncoBel. Former VP New Pharma Technologies & Academic Liaison, UCB New Medicines
11:00 Morning refreshments
11:20 Inhalation delivery systems: the challenges and opportunities
*
Retention in the lung
*
Absorption from the lung
*
Safety and efficacy
*
Industry challenges & open innovation
Dr. Ben Forbes
Senior Lecturer in Pharmaceutics, King’s College, London
12:00 Sponsor Spotlight Session
Take this unique opportunity to be a part of the conference theme, network, share ideas and provide an overview of your product/services to the audience.
12:40 Networking lunch
13:40 Virtual training course for development of nanoparticulate dosage forms From API to final nanoparticulate drug products
*
Pros and cons of various particle size reduction technologies
*
Practical development tools (Stabilizer screening, Particle size measurements, Solid state analysis, Final dosage form manufacturing, Dissolution aspects, Stability studies)
*
Biopharmaceutical aspects
Dr. Sophie Van Tomme
Pharmaceutical Scientist, Abbott
14:20 Targeted drug delivery using microbubble - An overview
*
Possible approaches of delivering drug using microbubble
*
Microbubble production technologies and its effect on delivery
*
Drug delivery mechanism
*
Advantages and challenges
*
Summary
Ketan Pancholi
Lecturer, The Robert Gordon University
15:00 Afternoon Refreshments
15:20 IMAG(IN)E global-release local - IMAGE guided ultra sound-triggered drug delivery for RNAi-based therapy
*
Medical imaging technologies are becoming an integral part of therapeutic interventions. The development of ultrasound techniques that could non-invasively trigger the delivery of new drug formats such as RNAi therapeutics at a targeted location opens up exciting possibilities for advancing personalized medicine. A key success factor for the effective translation of new drug delivery concepts into clinical practice are partnerships with leading academic, medical institutions and industrial partners.
*
Philips’ image-guided ultrasound-mediated drug delivery platform offers researchers a unique approach to investigating the delivery of various therapeutic molecules and capitalizes upon Philips’ existing expertise in medical imaging technologies for diagnosis, therapy planning and minimally-invasive medical procedures. We show advances in temperature sensitive liposomes with incorporated drugs and MRI-imaging labels as well as pressure-sensitive microbubbles with specific ultrasound-imaging and drug release characteristics for the local delivery of nucleic-acid based therapeutics including siRNA.
Dr. Oliver Steinbach
Department Head, Philips Research Laboratories
16:00 Ocular Drug Delivery Systems
*
Challenges and advantages of conventional dosage forms
*
Analysing recent trends in ocular inserts
*
Closing remarks from the chair
16:50 Networking drinks
Day 2
6th Annual Drug Delivery Systems
Wednesday 2nd February 2011
09:00 Registration and refreshments
09:30 Opening address from the chair
09:40 Targeted drug delivery strategies in cancer therapy: The evolution of early concepts
*
Naive concepts in early targeting
*
Toxins as chemotherapeutic agents,
*
Liposomes as Toxin Vectors
*
Physiological barriers to success
*
The emergence of holistic strategies.
Dr. Deirdre McIntosh
Director, McIntosh Scientific Advice Services
10:20 Protein and peptide drug delivery strategies for product lifecycle management
*
Why is new biologic delivery technologies needed?
*
Innovative technologies to deliver therapeutic macromolecules:
- CriticalMix – injectable sustained release of macromolecules
- CriticalSorb – systemic delivery of macromolecules via the intranasal route
Dr. Andrew Lewis
Operations Director, Critical Pharmaceuticals
11:00 Morning refreshments
11:20 Drug synthesis and delivery IP due diligence
*
Importance of IP protecting manufacturing process and drug delivery technology in late stage investments
*
Typical issues around manufacturing process patents
*
Typical issues around drug delivery patents
*
Subsistence of Supplementary Protection Certificates
*
Regulatory data protection and orphan drug
*
Protection in late stage investments
Gerry Kamstra
Partner, IP & Life Sciences, Bird and Bird
12:00 Parenteral sustained release drug delivery systems - Status and perspective
Gerrit Hauck
Head PSD R&D Operations, Sanofi-Aventis
12:40 Networking lunch
13:40 Innovations in generic development of drug delivery systems
*
Drug delivery systems
*
Challenges in generic development of drug delivery systems
- Regulatory
- IP
- Bio requirements
- Technological
*
Case studies
Dr. Rajan K. Verma
Senior Manager Early Development Formulations – Generics Integrated Product Development (IPDO)
Dr Reddy’s Laboratories]
14:20 Different strategies in managing a drug delivery alliance
Matthew Roe
Senior Director-Business Development and Licensing, Genzyme
15:00 Afternoon refreshments
15:20 Sponsor Spotlight Session
Take this unique opportunity to be a part of the conference theme, network, share ideas and provide an overview of your product/services to the audience.
16:00 Drug delivery in diabetes
*
Examining various techniques
*
Discussing emerging insulin delivery methods
*
Understanding pricing and reimbursement
16:40 Chair’s closing remarks
16:50 End of Conference
For more information visit
http://www.bharatbook.com/detail.asp?id=111630&rt=Conference-on-6th-Annual-Drug-Delivery-Systems.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
No comments:
Post a Comment